Le Hanh Hua, ECTRIMS 2021: Siponimod’s Efficacy on Secondary Progressive MS – Post-hoc Analysis of the EXPAND Study

It was a pleasure to meet with Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the use of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study.

The abstract entitled: ‘Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study’ was presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 13-15 October 2021.

Questions:

1. What did the EXPAND study teach us about the efficacy and safety of siponimod in the treatment of patients with secondary progressive multiple sclerosis (SPMS)?
2. What were the aims and design of the post-hoc analysis of the EXPAND study?
3. What were the findings of this analysis and how did these compare to the overall patient cohort?
4. What were the limitations of the analysis?
5. What can we do to ensure clinical trials and research become more diverse?

Disclosures: Le Hanh Hua receives personal fees for speaking, consulting and advisory board activities from Biogen, Celgene, EMD Serono, Genentech, Genzyme and Novartis. The study was supported by Novartis Pharmaceuticals Corporation.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of ECTRIMS Congress, Virtual 2021